Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core MSCI EAFE ETF (IEFA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

iShares Core MSCI EAFE ETFTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

iShares Core MSCI EAFE ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Core MSCI EAFE ETF trades at $101.04, while State Street SPDR S&P Biotech ETF trades at $159.13. Which is the better fit depends on your goals.

IEFAXBI
Sector
Broad Market / FactorBroad Market / Factor
52-Week High
$101.09$164.28
52-Week Low
$84.72$86.92

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core MSCI EAFE ETF

IEFA trades at $100.895, up 0.36% today, with a bullish technical signal from moving averages and strong trend momentum indicated by ADX. The fund focuses on developed international markets excluding the U.S. and Canada, offering diversification benefits and a dividend yield of 3.30% as noted by The Motley Fool on June 13, 2026. Recent news highlights its cost efficiency compared to peers like EFA, with an expense ratio of 0.07%.

Outlook is positive due to defensive inflows and Fed cut potential, but risks include capped upside from covered call strategies and concentration in non-U.S. markets. Analyst sentiment is mixed, with some favoring broader ETFs like VXUS for higher returns.

State Street SPDR S&P Biotech ETF

XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.

The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.

Returns comparison

Trailing returns across standard periods

About iShares Core MSCI EAFE ETF

IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.

Read more on IEFA

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI